We propose a comprehensive genetic and molecular epidemiological investigation of the role of Myeloid Derived Suppressor Cells (MDSCs) in ovarian cancer prognosis. These cells have been shown to be associated with defective dendritic cell function and suppression of CD4+ and CD8+ T cell response via multiple mechanisms. This is a highly significant project for risk classification for prognosis, and identification of factors that may interfere with the efficacy of immunotherapeutic treatment approaches in ovarian cancer patients. To achieve this objective we propose three innovative aims that allow the first comprehensive investigation of MDSC in ovarian carcinogenesis in a well-designed epidemiologic framework.
In Specific Aim 1, we will benefit from our strong collaborative ties with the Ovarian Cancer Association Consortium, which will allow us access to a very large cohort of over 13,000 of ovarian cancer patients in which we will measure the relationship between single nucleotide polymorphisms (SNPs) in genes hypothesized to be associated with MDSC activity and ovarian cancer outcomes (survival and recurrence). This is the first study to consider the association between SNPs in genes believed relevant to modulating MDSC levels and cancer prognosis in general and ovarian cancer prognosis in particular.
In Specific Aim 2, we will assess the association between clinical characteristics and short-term outcomes with MDSC frequencies in tumor and blood samples prior to and post treatment in 320 serous ovarian cancer patients. Lastly in Aim 3 we test for association of significant SNPs (Aim 1) with MDSC levels in blood and tumor tissue from patients with ovarian cancer to help determine if MDSC levels are possibly driving the significant associations of SNPs with clinical outcomes seen in Aim 1. Importantly, from this information we will build a clinical instrument using predictive models in order to identify patients susceptible to poor outcomes. Together these three aims allow for a comprehensive investigation of the roles of phenotypic expression and genetic variation in an important immune pathway relevant to susceptibility to poor clinical characteristics at diagnosis and outcomes in ovarian cancer.

Public Health Relevance

The proposed research will comprehensively study the association between MDSCs and ovarian cancer prognosis. If strong associations are identified, such information can be used in the clinical setting in identifying most promising candidates for novel immunotherapeutic approaches.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Wang, Zehua; Yang, Bo; Zhang, Min et al. (2018) lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell 33:706-720.e9
Mayor, Paul C; Eng, Kevin H; Singel, Kelly L et al. (2018) Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 141:1028-1035
Harris, Holly R; Babic, Ana; Webb, Penelope M et al. (2018) Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 27:174-182
Shenoy, Gautam N; Loyall, Jenni; Berenson, Charles S et al. (2018) Sialic Acid-Dependent Inhibition of T Cells by Exosomal Ganglioside GD3 in Ovarian Tumor Microenvironments. J Immunol 201:3750-3758
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Wang, Yue; Wang, Zehua; Xu, Jieni et al. (2018) Systematic identification of non-coding pharmacogenomic landscape in cancer. Nat Commun 9:3192
Minlikeeva, Albina N; Moysich, Kirsten B; Mayor, Paul C et al. (2018) Anthropometric characteristics and ovarian cancer risk and survival. Cancer Causes Control 29:201-212
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Szender, J Brian; Kaur, Jasmine; Clayback, Katherine et al. (2018) Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer 28:26-33

Showing the most recent 10 out of 128 publications